当前位置:首页 > 报告详情

药明康德-JPM-20240110 .pdf

上传人: 2*** 编号:155907 2024-01-05 25页 2.43MB

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
WuXi AppTec, a global leader in CRDMO (Contract Research and Development Manufacturing Organization) and CTDMO (Contract Testing, Development, and Manufacturing Organization) platforms, reports robust growth in its small molecule pipeline and expanding capabilities in oligo and peptide synthesis, contributing to a sustainable increase in revenue. The company is well-positioned to cater to the escalating demand for innovative drugs, with a strong and loyal customer base, and expects a 2-3% revenue growth in 2023, excluding the impact of COVID-19 commercial projects. WuXi AppTec aims to enhance operational efficiency, expecting an adjusted non-IFRS gross profit margin of 41.7-42.1% and an adjusted non-IFRS net profit exceeding RMB 10 billion. The company is committed to investing in comprehensive capabilities and new capacities to better serve the global market, with a focus on driving long-term sustainable growth.
"如何看待 WuXi AppTec 的全球市场份额增长?" "WuXi AppTec 在小分子药物研发领域的优势是什么?" "WuXi AppTec 如何平衡业务增长与运营效率?"
客服
商务合作
小程序
服务号
折叠